23andMe SPAC Presentation Deck
Strategic Collaboration
With gsk
$300M 50/50
equity
investment
shared costs
and profits
Access to
GSK technology and
platforms
"Our work with 23andMe is exceeding expectations and helping us advance a
new way of thinking about drug discovery, one driven by genetics and the
DNA we inherit. The insights of why some people are protected from or are at
greater risk for certain diseases can lead to genetically validated targets that
are at least twice as successful in clinical trials."
1 And some GSK unilateral programs.
Dr. Hal Barron, Chief Scientific Officer & President R&D, GSK (2021)
30+
joint profit sharing
programs¹
Inception-to-date targets discovered:
Oncology
Cardiovascular
Immunology
Metabolic Disease
Neurology
23andMe Confidential and Proprietary Information 26View entire presentation